Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Vaccines - Argentina

Argentina
  • In Argentina, the Vaccines market is anticipated to witness a substantial growth in revenue, with projections indicating that it will reach US$621.80m by the year 2024.
  • Moreover, it is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of -6.04%, resulting in a market volume of US$455.40m by 2029.
  • When compared to other countries worldwide, United States is forecasted to generate the highest revenue in the Vaccines market, with an estimated value of US$29.12bn in 2024.
  • The Argentine government has implemented various initiatives to increase vaccine accessibility and distribution across the country, leading to a significant increase in vaccination rates.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

In-Scope

  • Vaccines against infectious diseases
  • Prophylactic and therapeutic vaccines
  • Flu vaccines
  • COVID-19 vaccines

Out-Of-Scope

  • Sera and gammaglobulins
  • Antivirals
  • Antibiotics
Vaccines: market data & analysis - Cover

Market Insights report

Vaccines: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The Vaccines market in Argentina has experienced significant growth in recent years.

    Customer preferences:
    Customers in Argentina are increasingly seeking out vaccines for a variety of reasons. One major factor is the growing awareness of the importance of preventive healthcare measures. Additionally, the government has implemented various vaccination campaigns to combat diseases such as influenza, meningitis, and HPV, which has increased demand for vaccines.

    Trends in the market:
    The vaccines market in Argentina has seen a trend towards the development of new and innovative vaccines. This has been driven by the need to combat emerging diseases and the growing demand for more effective vaccines. Furthermore, there has been an increase in the number of private vaccination clinics, which has led to greater competition in the market.

    Local special circumstances:
    Argentina has a well-established pharmaceutical industry, which has helped to support the growth of the vaccines market. Additionally, the government has implemented various policies and programs to support the development and distribution of vaccines. However, there have been challenges in the market, including issues with vaccine supply and distribution, as well as concerns around vaccine safety.

    Underlying macroeconomic factors:
    The growth of the vaccines market in Argentina has been supported by a number of underlying macroeconomic factors. These include a growing population, increasing healthcare spending, and a focus on preventive healthcare measures. Additionally, the government has implemented various policies and programs to support the development and distribution of vaccines, which has helped to drive growth in the market. However, there have been challenges in the market, including issues with vaccine supply and distribution, as well as concerns around vaccine safety.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Vaccines: market data & analysis - BackgroundVaccines: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.